We conducted an analysis of TCGA primary prostate adenocarcinoma (PRAD) mRNA-seq data to compare two groups: a FOXA1 mutant group and a mutation-negative (control) group. The gene discussed is FOXA1; the disease is prostate adenocarcinoma.